Technical
Channels
Drug Discovery Drug Development Drug Manufacturing Drug Delivery
Clinical Trials Regulatory and Legal Alliances and Mergers QA/QC and Compliance
Pharmaceutical Processing and Packaging
Ads by Google
Change text size [+] [-]
Pall presents five-year business plan
Tuesday, November 18, 2008
 Email This |  Printer Friendly

Pall Corp hosted an investor conference at the Grand Hyatt Hotel in New York City late last month.

The company presented its five-year strategic business plan for fiscal 2009 - 2013 to a group of financial analysts.

The presentation was also webcast live to a broader audience.

By the end of Pall's new five-year plan, sales CAGR is targeted to increase to between 7% and 9% with earnings per share ranging from $4.25 to $5.60, excluding restructuring and other charges and the impact of currency translation.

It has also updated guidance for fiscal 2009.

Sales are projected to grow between 4% and 6.5% with earnings per share of $2.10 to $2.30, excluding restructuring and other charges and the impact of currency translation.

The new plan calls for the establishment of a Swiss entity as part of the company's initiatives to rationalize its European infrastructure.

The new company, located in the canton of Fribourg, will lead and support sales, manufacturing, supply chain and other European functions.

The company also provided a target tax rate of 25-27% by fiscal 2013.


Share this:   Del.icio.us | 
Ask the Expert

Discovery of Cell Water Gate May Lead to New Cancer Drugs

Digital Edition



The R&D outsourcing (CRO) industry in India is currently ahead of that of China’s.
Yes
No
Maybe
View results


ABOUT PHARMA ASIA | FREE SUBSCRIPTION | CONTACT US

© 2009 Reed Business Information Asia, a division of Reed Elsevier Inc. All rights reserved.
Use of this Web site is subjected to its Terms and Conditions of Use. View our Privacy Policy